Clinical trials: Exposure
HIV, Antenatal Care
Enhancing Communication on Relationship Preservation, Safer Conception and PrEP to Promote HIV Testing in Uganda
Our novel communication strategy aims to promote HIV testing in Uganda with reassuring messages about the ability to have stable relationships and healthy families with the increased availability of pre-exposure prophylaxis…
- Conditions
- HIV, Antenatal Care, Antiretroviral Therapy, Pre-Exposure Prophylaxis
- Trial name
- NCT06647797
- Testing
- HOPE Clinical Communication Campaign
- Where
- 2 sites in Uganda
- Volunteers
- 22,359 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens
This dose finding, multi-cohort study is designed to evaluate the safety and efficacy of intradermally-injectedTNX-2100, synthesized SARS-CoV-2 peptide antigens and assess the presence and magnitude of DTH reactions.
- Trial name
- COVID-19 DTH (NCT05216510)
- Testing
- TNX-2110, TNX-2120, TNX-2130
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Tonix Pharmaceuticals, Inc.
HIV Exposure, HIV Infection
Early Versus Delayed BCG Vaccination of HIV-exposed Infants
In sub-Saharan Africa (SSA), more than 300,000 babies with HIV die each year. HIV-infected children develop AIDS and die faster in SSA than those in developed countries.
- Trial name
- NCT02062580
- Testing
- BCG
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
HIV
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.
- Trial name
- NCT01214759
- Testing
- Truvada, Raltegravir
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- The University of Texas Health Science Center, Houston
HIV/AIDS, HIV Infections
Treatment Options for Protease Inhibitor-exposed Children
The investigators hypothesize that switching to a regimen based on efavirenz will be as effective and safe as remaining on a regimen based on Lopinavir/ritonavir for HIV-infected children.
- Trial name
- NEVEREST-III (NCT01146873)
- Testing
- Efavirenz (EFV), Lopinavir/ritonavir (LPV/r), Stavudine (D4T)
- Where
- South Africa
- Volunteers
- 300 people
- Sponsor
- Columbia University
Arsenic Metabolites Measured in Urine
A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh
Roughly 140 million people worldwide are chronically exposed to As-contaminated drinking water at concentrations exceeding the World Health Organization (WHO) standard of 10 µg/L.
- Trial name
- CABS (NCT01749982)
- Testing
- Choline bitartrate, Betaine, Choline bitartrate + Betaine
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Columbia University
Fear of Flying
Targeting Reconsolidation to Prevent Return of Fear
The overall aim of this project is to determine if using a cue to trigger (and reactivate) the fear memory 10 minutes prior to exposure treatment sessions leads to less anxiety in patients with a fear of flying.
- Trial name
- NCT01623830
- Testing
- Virtual Reality Exposure Therapy
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Emory University
Ozone Exposure During Rest and Exercise
Susceptibility of Cardiorespiratory Responses to Ozone During Cycling Exercise
Ground level ozone (O3) is a common airborne pollutant that is well recognized to cause negative respiratory symptoms and impair pulmonary function.
- Trial name
- NCT05473000
- Testing
- Exercise, Ozone, Room air
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Edentulous
Implant Placement With Simultaneous Gum Grafting
This study is a comparison of implant placed and simultaneously grafted with either autogenous connective tissue or a connective tissue allograft.
- Trial name
- NCT01431144
- Testing
- connective tissue autograft, connective tissue allograft
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Louisville
COPD
Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe…
- Trial name
- GOLDEN7 (NCT02512302)
- Testing
- SUN-101 via eFlow nebulizer, SUN-101 via eFlow nebulizer with activated charcoal, Seebri® Breezhaler®
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Sunovion Respiratory Development Inc.
Rheumatoid Arthritis
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
This study was intended to assess the safety, efficacy, and response to treatment using the American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) and to investigate a potential biomarker profile…
- Trial name
- NCT00504595
- Testing
- ACZ885 (investigational)
- Where
- 4 sites in Russia, Spain and 2 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novartis
HIV/AIDS, Adherence
Monitoring Pre-exposure Prophylaxis for Young Adult Women
Next generation real-time monitoring for PrEP adherence in young Kenyan women
- Trial name
- MPYA (NCT02915367)
- Testing
- SMS Reminders
- Where
- 2 sites in Kenya
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Late-onset Pompe Disease
BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)
Study 701-301 is a single-arm, open-label, switchover study in patients with late-onset Pompe disease who have been receiving treatment with recombinant human acid alpha-glucosidase (rhGAA) for 48 weeks or longer.
- Trial name
- NCT01924845
- Testing
- BMN 701
- Where
- 22 sites in United States, Belgium and 6 more
- Volunteers
- 24 people
- Sponsor
- BioMarin Pharmaceutical
Innate Inflammatory Response, Vaccination
PFAS Exposure and Immune Response to Vaccination in Adults
This clinical trial aims to investigate how exposure to Perfluorononanoic acid (PFNA), a type of per- and polyfluoroalkyl substance (PFAS), affects the immune response to the standard tetanus and diphtheria (Td) vaccine.
- Conditions
- Innate Inflammatory Response, Vaccination, Diphtheria, Tetanus
- Trial name
- NCT06588530
- Testing
- TENIVAC
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Sexually Transmitted Diseases
Doxy-Post-exposure Prophylaxis
The goal of this project is to collect data regarding the ability of various oral doses of doxycycline to penetrate mucosal tissues in men and women to inform the combination of doxycycline with antiretrovirals (ARVs) for the…
- Trial name
- DOXY-PEP (NCT05853120)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Emory University
Leprosy
Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar
This is a cluster randomized trial on effectiveness of different modalities of Single Double Dose of Rifampicin Post-Exposure Prophylaxis (SDDR-PEP) for leprosy in the Comoros (Anjouan and Mohéli) and Madagascar.
- Trial name
- PEOPLE (NCT03662022)
- Testing
- Rifampicin
- Where
- 3 sites in Comoros, Madagascar
- Volunteers
- 144,000 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV Infections
The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
Pre-exposure prophylaxis (PrEP) is a method of preventing HIV infection through the use of antiretroviral (ARV) medications before exposure to HIV.
- Trial name
- ADAPT (NCT01327651)
- Testing
- Daily dosing, Time-driven dosing, Event-driven dosing
- Where
- 3 sites in United States, South Africa and 1 more
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
Pre-Exposure Prophylaxis (PrEP)
eSTEP: An Integrated mHealth Intervention to Engage High-risk Individuals Along the Full PrEP Care Continuum
The long-term goal of this research is to develop a theoretically grounded, effective, accessible and sustainable mHealth PrEP care continuum intervention for men who have sex with men (MSM) and transgender women (TW).
- Trial name
- eSTEP (NCT06159582)
- Testing
- eSTEP, Usual Care
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- San Diego State University
Lung Diseases, Interstitial
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing Interstitial Lung Disease (ILD).
- Trial name
- InPedILD® (NCT04093024)
- Testing
- Nintedanib
- Where
- 43 sites in United States, Argentina and 19 more
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Geographic Atrophy
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in…
- Trial name
- NCT02288559
- Testing
- Lampalizumab
- Where
- 36 sites in United States
- Volunteers
- 96 people
- Sponsor
- Genentech, Inc.